ReviewTexas Heart Institute journal2005
Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.
Review in Texas Heart Institute journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Direct Oral Anticoagulants vs. Vitamin K Antagonists for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Article
- Multimodality Imaging in Cardiac Amyloidosis.Journal of clinical medicine · 2025Review
- A case series of patients with cardiac amyloidosis evaluated at a Colombian university hospital.Frontiers in cardiovascular medicine · 2025Article
- Ascites revealing peritoneal amyloidosis and IgG kappa multiple myeloma: A case report.Radiology case reports · 2024Article
- Diagnostic value of LGE and T1 mapping in multiple myeloma patients'heart.BMC cardiovascular disorders · 2024Article
- Part I: Cutaneous manifestations of cardiovascular disease.Journal of the American Academy of Dermatology · 2023Review
- Amyloidosis of the Heart: A Comprehensive Review.Cureus · 2023Review
- Cardiac Amyloidosis: A Rare TTR Mutation Found in an Asian Female.Journal of cardiovascular development and disease · 2023Article
- Signal peptide stabilizes folding and inhibits misfolding of serum amyloid A.Protein science : a publication of the Protein Society · 2022Article
- Recovery from AA amyloidosis-cardiomyopathy complexed with unicentric Castleman disease.BMJ case reports · 2022Article
- Re-Definition of the Epidemiology of Cardiac Amyloidosis.Biomedicines · 2022Review
- Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options.Cardiology and therapy · 2022Review
- A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction.American journal of cardiovascular disease · 2022Review
- Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study.JACC. CardioOncology · 2021Article
- Cardiac amyloidosis-A review of current literature for the practicing physician.Clinical cardiology · 2021Review
- Diagnosis of Cardiac Involvement in Amyloid A Amyloidosis by Cardiovascular Magnetic Resonance Imaging.Frontiers in cardiovascular medicine · 2021Article
- AL type cardiac amyloidosis: a devastating fatal disease.Journal of community hospital internal medicine perspectives · 2021Article
- The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data.Neurology and therapy · 2020Article
- A Novel Method for Amyloid Detection in Human Tissue Load Using a Fluorescent Dye - Congo Red Analogue.Sovremennye tekhnologii v meditsine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidosis comprises a unique group of diseases that share in common the extracellular deposition of insoluble fibrillar proteins in organs and tissues. Cardiovascular amyloidosis can be primary, a part of systemic amyloidosis, or a result of chronic systemic diseases elsewhere in the body. The most common presentations are congestive heart failure-mainly a restrictive infiltrative pattern--and conduction system disturbances. Recent developments in imaging techniques and extracardiac tissue sampling have minimized the need for invasive endomyocardial biopsy for amyloidosis. Despite advances in treatment, the prognosis for patients with amyloidosis is still poor and depends on the underlying disease type. Herein, we present new insights and recent advances in cardiovascular amyloidosis.
Indexed as
Identifiers
16107109PMC1163465W1945652469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.